A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

被引：1
|
作者：
Kristeleit, Rebecca Sophie
Brown, Nicholas F.
Hess, Dagmar
Joerger, Markus
Von Moos, Roger
Rodon, Jordi
Hierro, Cinta
Childs, Alexa
Stathis, Anastasios
Dimitrijevic, Sasa
Stumm, Michael
Herrmann, Richard
Sessa, Cristiana
Bize, Vincent
Hess, Viviane
Wicki, Andreas
机构：
[1] UCL, Inst Canc, London, England
[2] UCL, London, England
[3] Kantonsspital St Gallen, Eggersriet, Switzerland
[4] Cantonal Hosp, St Gallen, Switzerland
[5] VHIO, Barcelona, Spain
[6] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[7] PIQUR Therapeut AG, Basel, Switzerland
[8] Piqur Pharma, Basel, Switzerland
[9] Univ Hosp, Riehen, Switzerland
[10] IOSI, Bellinzona, Switzerland
[11] SAKK Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
[12] Univ Spital Basel, Basel, Switzerland
[13] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2592
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors
    Machacek, Matthias
    Renaud, Lionel
    Dimitrijevic, Sasa
    Schmitz, Debora
    Ivanova, Elena
    Jorga, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
    Wicki, Andreas
    Brown, Nicholas
    Xyrafas, Alexandros
    Bize, Vincent
    Hawle, Hanne
    Berardi, Simona
    Cmiljanovic, Natasa
    Cmiljanovic, Vladimir
    Stumm, Michael
    Dimitrijevic, Sasa
    Herrmann, Richard
    Pretre, Vincent
    Ritschard, Reto
    Tzankov, Alexandar
    Hess, Viviane
    Childs, Alexa
    Hierro, Cinta
    Rodon, Jordi
    Hess, Dagmar
    Joerger, Markus
    von Moos, Roger
    Sessa, Cristiana
    Kristeleit, Rebecca
    EUROPEAN JOURNAL OF CANCER, 2018, 96 : 6 - 16
  • [3] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma
    Collins, Graham P.
    Popat, Rakesh
    Stathis, Anastasios
    Krasniqi, Fatime
    Eyre, Toby A.
    Ng, Chin Hin
    El-Sharkawi, Dima
    Schmidt, Christian
    Wicki, Andreas
    Ivanova, Elena
    Schmitz, Debora
    Dimitrijevic, Sasa
    Dreyling, Martin H.
    BLOOD, 2016, 128 (22)
  • [5] Final results of the pharmacodynamic (PD) data of PQR309-001 a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors
    Wicki, Andreas
    Pretre, Vincent
    Ritschard, Reto
    Brown, Nicholas
    Bize, Vincent
    Fabbro, Thomas
    Cmiljanovic, Natasa
    Dimitrijevic, Sasa
    Schmitz, Deborah
    Stumm, Michael
    Kristeleit, Rebecca
    CANCER RESEARCH, 2016, 76
  • [6] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [7] A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
    Patnaik, A.
    Appleman, L. J.
    Mountz, J. M.
    Ramanathan, R. K.
    Beeram, M.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Lotze, M. T.
    Petro, D. P.
    Laymon, C.
    Paige, L.
    Rajagopalan, P.
    Jeffers, M.
    Roth, D.
    Dubowy, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [9] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [10] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors
    Burris, H.
    Rodon, J.
    Sharma, S.
    Herbst, R. S.
    Tabernero, J.
    Infante, J. R.
    Silva, A.
    Demanse, D.
    Hackl, W.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345